Alpha-amylase (AMY) (AMY)

Alpha-amylase is a calcium-dependent metalloenzyme that catalyzes the hydrolysis of alpha-1,4-glycosidic linkages in starch, glycogen, and various oligosaccharides (StatPearls, 2023). In humans, it is primarily synthesized and secreted by the salivary glands (salivary alpha-amylase, AMY1) and the pancreas (pancreatic alpha-amylase, AMY2), playing a fundamental role in the initial stages of carbohydrate digestion (UniProt, 2024). By breaking down complex polysaccharides into smaller units like maltose and maltotriose, it facilitates the subsequent action of alpha-glucosidases in the brush border of the small intestine (PubMed, 2021). This enzyme is a significant therapeutic target for managing metabolic disorders, particularly type 2 diabetes mellitus and obesity, where its inhibition helps control postprandial blood glucose spikes (PubChem, 2024). Drugs such as acarbose act as competitive inhibitors of alpha-amylase, effectively slowing the rate of glucose release and absorption into the bloodstream (NIH, 2023). Clinically, elevated levels of pancreatic amylase in the blood are used as a diagnostic biomarker for acute pancreatitis and other pancreatic injuries (StatPearls, 2023). However, pharmacological inhibition of this enzyme often leads to gastrointestinal side effects, such as flatulence and diarrhea, due to the fermentation of undigested carbohydrates by colonic bacteria (PubMed, 2022).

Other names

1,4-alpha-D-glucan glucanohydrolasePtyalinGlycogenaseSalivary alpha-amylasePancreatic alpha-amylaseAMY1AMY2

Competitive inhibition of alpha-amylase activity in the gastrointestinal tract, which delays the breakdown of starch and complex sugars into glucose, thereby reducing postprandial glycemic excursions (PubChem, 2024; NIH, 2023).